Heinz Feldmann, M.D., Ph.D.Rocky Mountain LaboratoriesBuilding 28, Room 2A100A903 South 4th StreetHamilton, MT 59840-2932Phone: email@example.com
Read about NIAID-supported research to develop a dual-purpose vaccine to protect humans and wildlife against Ebola and rabies.
Chief, Laboratory of Virology
Chief, Disease Modeling and Transmission Section
The Disease Modeling and Transmission Section was established in August 2008. Its mission is to study emerging and re-emerging viral pathogens, in particular those that cause hemorrhagic fever, with an aim of developing diagnostics, treatments, and vaccines. The section focuses on the lifecycle of certain viral pathogens that are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not available. The research objective is to learn how to interfere with the viral lifecycle and the virus-induced host responses to identify targets of intervention and to develop measures of prevention. Animal disease modeling is a critical component of all research objectives.
Heinz Feldmann graduated from medical school in 1987 (M.D.) and received his Ph.D. in 1988, both from the University of Marburg, Germany. His postdoctoral research was conducted in the field of virology (filoviruses and hantaviruses) at the Institute of Virology, University of Marburg, Germany, and the special pathogens branch at the Centers for Disease Control and Prevention in Atlanta, where he held a fellowship from the National Research Council. Following his postdoctoral training, he was as an assistant and associate professor with the Institute of Virology at the University of Marburg, Germany. During this time he was trained as an infectious disease specialist with a focus on laboratory diagnostics. From 1999 to 2008, Dr. Feldmann held the position of chief of the special pathogens program of the National Microbiology Laboratory, Public Health Agency of Canada. Since 2008, he has been the chief of Laboratory of Virology and the chief scientist at the RML BSL-4 laboratories. In addition, he is an associate professor with the department of medical microbiology, University of Manitoba. Dr. Feldmann is a laboratory expert on high containment viruses (BSL-4) and serves as a consultant on viral hemorrhagic fevers and related pathogens for the World Health Organization and, thus, has field experience and expertise in outbreak management. He is a member of national and international professional societies, an editor for Archives of Virology, and serves on the editorial board of several other journals. Dr. Feldmann is an external scientific reviewer for national and international organizations and serves as a scientific consultant for high containment laboratories. His professional interest is in the pathogenesis of hemorrhagic fever viruses, such as filoviruses, arenaviruses and bunyaviruses, and other emerging viral pathogens (containment level BSL-3 and BSL-4).
Laura Baseler, D.V.M., Graduate Student
Julie Callison, M.S., Biologist
Blair DeBuysscher, Graduate Student
Darryl Falzarano, Ph.D., Postdoctoral Fellow
Elaine Haddock, Ph.D., Biologist
Thomas Hoenen, Ph.D., Postdoctoral Fellow
Joshua Marceau, Graduate Student
Andrea Marzi, Ph.D., Staff Scientist
Joseph Prescott, Ph.D., Postdoctoral Fellow
Kyle Rosenke, Ph.D., Biologist
David Safronetz, Ph.D., Staff Scientist
Emmie de Wit, Ph.D., Postdoctoral Fellow
Marko Zivcec, Graduate Student
Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, Lacasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC,Feldmann H, Geisbert TW. A hendra virus g glycoprotein subunit vaccine protects african green monkeys from nipah virus challenge. Sci Transl Med. 2012 Aug 8;4(146):146ra107.
Safronetz D, Zivcec M, Lacasse R, Feldmann F, Rosenke R, Long D, Haddock E, Brining D, Gardner D, Feldmann H, Ebihara H. Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathog. 2011 Dec;7(12):e1002426.
Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011 Dec;85(23):12781-91.
Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter MS, Schnittler HJ, Feldmann H. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol. 2011 Jun;85(11):5406-14.
Grolla A, Jones SM, Fernando L, Strong JE, Ströher U, Möller P, Paweska JT, Burt F, Pablo Palma P, Sprecher A, Formenty P, Roth C, Feldmann H. The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg Outbreak in Angola. PLoS Negl Trop Dis. 2011 May;5(5):e1183.
Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Aranda CA, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H. Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J Virol. 2011 Feb;85(3):1214-23.
Visit PubMed for a complete publication listing.
Jones S, Feldmann H, Stroeher U, inventors. Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers. United States patent US 8,012,489. 6 Sep 2011.
Plummer F, Feldmann H, Jones S, Li Y, Bastien N, Brunham RC, Brooks-Wilson A, Astell C, Jones S, inventors; The Public Health Agency of Canada, assignee. SARS virus nucleotide and amino acid sequences and uses thereof. United States patent US 7,897,744. 1 Mar 2011.
Last Updated July 18, 2013